Study of NX-5948 Versus Pirtobrutinib in R/R CLL/SLL
NCT07516093Phase 3Recruiting
- Lead sponsor
- Nurix Therapeutics, Inc. (Industry)
- Enrollment
- 620 (estimated)
- Start date
- 3 Aug 2026
- Primary completion
- Oct 2029 (estimated)
- Study completion
- 1 Aug 2033
- Last update posted
- 31 Aug 2026
Design
- Study type
- Interventional
- Primary purpose
- Treatment
- Allocation
- Randomized
- Intervention model
- Parallel
- Masking
- None
- Arms
- 2
Interventions
- NX-5948 Drug
- Pirtobrutinib Drug
Conditions and primary outcome
- B-cell Lymphoma
- Chronic Lymphocytic Leukemia
- Small Lymphocytic Lymphoma
Primary outcome
Progression-free survival (PFS) as assessed by Independent Review Committee (IRC) (Up to approximately 3.5 years); Objective response rate (ORR) without partial response with lymphocytosis (PR-L) as assessed by IRC (Up to approximately 2.5 years)
Posted results on ClinicalTrials.gov
Results posted on ClinicalTrials.gov: No
Results from company and journal sources
No editor-confirmed results are on record for this study.
Publications
No PubMed citation lists NCT07516093.
CT-VCA trial quality
About CT-VCALoading CT-VCA scores…
Data integrity
Compare what the registry, company releases, FDA documents and publications say about this study.
Drugs on HealthTrade
Source
- NCT07516093 on ClinicalTrials.gov (opens in a new tab) Licence: public-domain. Read
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Listing a study does not mean NLM has evaluated it.
Nothing on this page is medical or investment advice.